Autres langues Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/05/2024			Varia. 5j.	Varia. 1 janv.
24,67 ^USD	-1,87 %		-1,48 %	-19,38 %

23/05	Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
20/05	Une étude d'Arrowhead Pharmaceuticals sur le traitement des maladies pulmonaires montre une baisse des sRAGE sériques chez les patients asthmatiques	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients	20/05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma	20/05
Arrowhead Pharmaceuticals : TIDES USA 2024 TIDES 2024 AdiposeTIDES 2024 ARO-SOD1	17/05
Arrowhead Pharmaceuticals : 2024 Second Quarter Results Prepared Remarks	10/05
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2	09/05
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results	09/05
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	03/05
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma	02/05
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences	29/04
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars	26/04
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results	24/04
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24/04
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24/04
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07/04
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07/04
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	01/04
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data	25/03
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	25/03
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	08/03
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation	08/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Autres langues

Filtres